First Financial Bank Trust Division lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 0.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 180,493 shares of the biopharmaceutical company’s stock after selling 1,384 shares during the period. Pfizer makes up approximately 1.1% of First Financial Bank Trust Division’s portfolio, making the stock its 26th largest position. First Financial Bank Trust Division’s holdings in Pfizer were worth $6,444,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of PFE. Altfest L J & Co. Inc. boosted its stake in shares of Pfizer by 67.0% during the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after acquiring an additional 43,024 shares during the last quarter. HL Financial Services LLC boosted its stake in shares of Pfizer by 1.1% during the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after acquiring an additional 35,744 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Pfizer during the 1st quarter worth $13,342,000. Searle & CO. boosted its stake in shares of Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after acquiring an additional 38,500 shares during the last quarter. Finally, Hartford Financial Management Inc. boosted its stake in shares of Pfizer by 10.8% during the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 835 shares during the last quarter. 69.75% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) opened at $36.14 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a one year low of $30.90 and a one year high of $37.35. The firm has a market cap of $215,420.00, a price-to-earnings ratio of 22.17, a P/E/G ratio of 2.56 and a beta of 1.01.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.76%. Pfizer’s payout ratio is 78.53%.
Pfizer announced that its Board of Directors has initiated a share repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.
Several brokerages have recently weighed in on PFE. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, December 15th. Jefferies Group set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Monday, October 16th. Deutsche Bank set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Finally, Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $38.77.
In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,800 shares of company stock worth $1,327,248. 0.06% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “First Financial Bank Trust Division Has $6.44 Million Position in Pfizer Inc. (PFE)” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/24/first-financial-bank-trust-division-has-6-44-million-position-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.